Loading
SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development. Besides testosterone, it can also act on other steroids, including progesterone, androstenedione, and corticoids, producing metabolites with diverse roles. Hence, it plays a central role in sexual differentiation and androgen physiology. Location: Microsome membrane; Endoplasmic reticulum membrane (UniProt). Locus 5p15.31 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"SRD5A1" OR ABSTRACT:"SRD5A1" OR TITLE:"steroid 5 alpha-reductase 1" OR ABSTRACT:"steroid 5 alpha-reductase 1" OR TITLE:"3-oxo-5-alpha-steroid 4-dehydrogenase 1" OR ABSTRACT:"3-oxo-5-alpha-steroid 4-dehydrogenase 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRD5A1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/srd5a1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/srd5a1.json. Licence CC BY-NC 4.0.